Evidence map›Paper›PMID 34453189›Full record

ArticleAnnals of hematology2021

Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.

Francine Chenou, Bidossessi Wilfried Hounkpe, Igor de Farias Domingos, Wouitchékpo Vincent Tonassé, Thais Helena Chaves Batista, Rodrigo Marcionilo Santana, Gabriela da Silva Arcanjo, Adekunle Emmanuel Alagbe, Aderson da Silva Araújo, Antonio Roberto Lucena-Araújo and 5 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Francine ChenouDepartment of Clinical Pathology, School of Medical Sciences, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil.
Bidossessi Wilfried HounkpeHematology and Hemotherapy Center, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil.
Igor de Farias DomingosDepartment of Clinical and Toxicological Analysis, Federal University of Rio Grande Do Norte, Natal, RN, Brazil.
Wouitchékpo Vincent TonasséDepartment of Clinical Pathology, School of Medical Sciences, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil.
Thais Helena Chaves BatistaGenetics Postgraduate Program, Federal University of Pernambuco (UFPE), Recife, Pernambuco, Brazil.
Rodrigo Marcionilo SantanaGenetics Postgraduate Program, Federal University of Pernambuco (UFPE), Recife, Pernambuco, Brazil.
Gabriela da Silva ArcanjoGenetics Postgraduate Program, Federal University of Pernambuco (UFPE), Recife, Pernambuco, Brazil.
Adekunle Emmanuel AlagbeDepartment of Clinical Pathology, School of Medical Sciences, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil.
Aderson da Silva AraújoHematology and Hemotherapy Foundation of Pernambuco (HEMOPE), Pernambuco, Recife, Brazil.
Antonio Roberto Lucena-AraújoGenetics Postgraduate Program, Federal University of Pernambuco (UFPE), Recife, Pernambuco, Brazil.
Marcos Andre Cavalcanti BezerraGenetics Postgraduate Program, Federal University of Pernambuco (UFPE), Recife, Pernambuco, Brazil.
Fernando Ferreira CostaHematology and Hemotherapy Center, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil.
Maria de Fátima SonatiDepartment of Clinical Pathology, School of Medical Sciences, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil.
Erich Vinicius De PaulaHematology and Hemotherapy Center, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil.
Magnun Nueldo Nunes Dos SantosDepartment of Clinical Pathology, School of Medical Sciences, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil. santosmn@unicamp.br.ORCID http://orcid.org/0000-0001-6908-4538
Universidade Estadual de Campinas (UNICAMP) · BRUniversidade Federal de Pernambuco · BRFundação Hemopa · BRUniversidade Federal do Rio Grande do Norte · BR

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2014/00984-3
6 · The paper itself

Abstract

Intravascular hemolysis (IH) contributes to the development of endothelial dysfunction (ED) in sickle cell anemia (SCA), and the effects of hydroxyurea (HU, the only approved drug that decreases the frequency and severity of vaso-oclussive crises) on IH and ED in SCA remain unclear. We evaluated and compared the markers of IH among steady-state adult Brazilians with SCA and HbAA individuals. Overall, this cross-sectional study enrolled 30 SCA patients not receiving HU therapy (HbSS), 25 SCA patients receiving HU therapy (HbSS_HU), and 32 HbAA volunteers (HbAA). The IH markers evaluated were serum Lactate Dehydrogenase (LDH), total heme, plasma hemoglobin (pHb), and soluble CD163 (sCD163). The ED markers analyzed were plasma von Willebrand factor (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo) levels, antigen of VWF-cleaving protease (ADAMTS13:Ag), thrombospondin-1, endothelin-1 levels, and ADAMTS13 Activity (ADAMTS13:Act). The levels of VWF:Ag, VWF:RCo, total heme, thrombospondin-1, and endothelin-1 were significantly higher in SCA patients (HbSS and HbSS_HU) compared to HbAA individuals. Also, pHb, LDH, and thrombospondin-1 levels were significantly higher in the HbSS group than in the HbSS_HU group. Contrarily, the levels of sCD163, ADAMTS13:Ag, and ADAMTS13:Act were significantly lower in both groups of SCA patients than HbAA controls, and ADAMTS13:Act levels were significantly lower in HbSS compared to HbSS_HU patients. The higher ADAMTS13 activity levels in those on HU therapy may be attributed to lower pHb and thrombospondin-1 levels as previously shown by in vitro studies that thrombospondin-1 and pHb are bound to VWF. Thus, VWF is restrained from ADAMTS13 activity and cleavage.

Indexed as

ADAMTS13 ProteinAdolescentAdultAnemia, Sickle CellAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersCD163 AntigenCross-Sectional StudiesEndothelium, VascularFemaleHemeHemoglobinsHemolysisHumansHydroxyureaADAMTS13 ProteinADAMTS13 protein, humanAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersCD163 AntigenHemeHemoglobinsHydroxyureaL-Lactate DehydrogenasePHB protein, humanProhibitinsReceptors, Cell SurfaceThrombospondin 1von Willebrand FactorBrazilian populationEndothelial dysfunctionHydroxyureaIntravascular hemolysisSickle cell anemia

Identifiers

PMID34453189
OpenAlexW3195018996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.